Pilot Study of Intra-Lesional MMR Vaccine Treatment for Difficult-to-Treat Tinea Cruris and Corporis in Patients Aged 10 to 60 Years

What this Trial Is About

Researchers are evaluating intra-lesional immunotherapy using the measles-mumps-rubella MMR vaccine as a treatment for recalcitrant tinea cruris and corporis. This condition involves persistent fungal infections that have not improved with standard antifungal treatments. The study targets patients aged 10 to 60 years who have experienced rapid progression, large affected skin areas, infections in multiple family members, rapid relapse, or suspected resistant strains of the fungus. The purpose is to assess the safety and therapeutic effect of this novel immunotherapy in a pilot setting. Participants will receive injections of the MMR vaccine directly into the active borders of their fungal lesions every two weeks for six weeks. If there is partial improvement but not full clearance after the initial treatment, the course may be extended for an additional six weeks, with up to six injection sessions total. In addition, patients will take pulse itraconazole during the first two weeks of the study. All participants receive the same treatment without a comparison or placebo group. Throughout the study, clinicians will monitor skin involvement and symptoms such as itching at each visit every two weeks, up to 6 weeks, with possible extension to 12 weeks if treatment continues. Safety assessments will track injection site reactions, fevers, lesion flares, and any rare serious allergic effects. The main outcome will be the percent reduction in the affected body surface area. Safety and tolerance of the injections will be observed continuously during treatment and extension periods. Participants are expected to be involved for up to 12 weeks in total.

A Pilot Study to Evaluate the Therapeutic Efficacy of Intra-Lesional Immunotherapy in Patients Aged 10-60 Years With Recalcitrant Tinea Cruris and Corporis